Table 2.

Results of the network meta-analysis on efficacy.

Placebo VS	Alirocumab	Evolocumab	Inclisiran	Lerodalcibep	Ongericimab	Tafolecimab
	LDL-C
HoFH	−35.45 (−83.20,9.91)	−30.67 (−75.20,13.70)	−1.98 (−51.65,48.53)	−25.35 (−89.18,38.57)	–	–
HeFH	−46.39 (−59.57,-32.02)	−55.49 (−75.34,-34.96)	−49.55 (−78.91,-20.68)	−58.49 (−87.53,-31.54)	−74.98 (−103.16,-45.65)	−59.47 (−90.28,-29.92)
OVERALL	−44.29 (−57.98,-29.65)	−50.59 (−68.10,-32.29)	−33.43 (−57.52,-4.57)	−52.49 (−77.82,-27.09)	−75.34 (−108.69,-40.58)	−59.85 (−93.53,-25.21)
	ApoB
HoFH	−29.86 (−68.82,9.13)	−23.34 (−62.00,15.17)	–	−12.02 (−68.50,44.51)	–
HeFH	−35.75 (−46.37,-23.68)	−45.12 (−61.98,-28.04)	−36.11 (−60.08,-10.63)	−45.78 (−70.32,-20.83)	−64.64 (−89.40,-38.90)	−58.93 (−85.14,-32.44)
OVERALL	−34.78 (−44.31,-24.33)	−41.07 (−53.97,-27.63)	−36.31 (−59.97,-13.00)	−39.68 (−58.32,-19.78)	−64.75 (−89.77,-40.69)	−58.51 (−83.78,-32.62)
	Lp(a)
HoFH	−28.31 (−66.31,9.84)	−7.08 (−44.11,30.47)	–	−7.91 (−61.50,46.29)	–	–
HeFH	−17.45 (−23.40,-8.20)	−28.92 (−38.11,-18.90)	–	–	−59.66 (−75.19,-44.02)	−39.23 (−57.59,-21.21)
OVERALL	−18.28 (−27.63,-7.59)	−24.58 (−35.08,-9.75)	–	−25.07 (−51.51,5.78)	−59.8 (−82.63,-36.69)	−39.11 (−63.29,-14.64)